Studies

A Phase 2 Study of Mosliciguat in PH-ILD

Internal Medicine Pulmonology Heart and Vascular Lung Disease Pulmonary Hypertension Heart Disease Adult Subjects Female Subjects Male Subjects

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

MK5475-013

Internal Medicine Pulmonology Heart and Vascular Pulmonary Hypertension Airway Disease Heart Disease Lung Disease Adult Subjects Female Subjects Male Subjects

Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take MK-5475 can walk farther in 6 minutes at Week 24 compared to people who take placebo.